Publications Search

Publications Search

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI. J Am Heart Assoc. 2022; epub ahead of print.

https://www.ahajournals.org/doi/epub/10.1161/JAHA.121.022937

https://pubmed.ncbi.nlm.nih.gov/35261279/

Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther. 2022 Mar 15; epub ahead of print.

https://www.sciencedirect.com/science/article/abs/pii/S0163725822000663

https://doi.org/10.1016/j.pharmthera.2022.108172

Singh N, Bhatt DL, Miller M, Steg G, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Mason RP, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220-222.

https://www.jacc.org/doi/10.1016/j.jacc.2021.11.005

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment. JAMA Netw Open. 2022;5(2):e2148172.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789004

https://pubmed.ncbi.nlm.nih.gov/35157055/

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT REVASC. Circulation. 2021;143:33-44.

https://pubmed.ncbi.nlm.nih.gov/33148016/

Picard F, Bhatt DL, Ducrocq G, Ohman EM, Goto S, Eagle KA, Wilson PWF, Smith SC, Elbez Y, Steg PG. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: an analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry. Int J Cardiol. 2021;340:96-104.

https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01297-3/fulltext

Verma S, Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif J-C, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation. 2021;144:1845-1855.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056290

https://pubmed.ncbi.nlm.nih.gov/34710343/

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Budoff M, Mason RP, Tardif JC, Boden WE, Ballantyne CM; REDUCE-IT Investigators. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144:1750-1759.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055560

https://pubmed.ncbi.nlm.nih.gov/34706555/
Fan W, Philip S, Toth PP, et al. Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300878

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext